← Leaderboards
Brad J Spellberg
La Biomed Res Inst/ Harbor Ucla Med Ctr
$22,247,101
Attributed
$23,623,444
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$21,815,256 · 15
AHRQ$1,808,188 · 1
By mechanism
R01$16,669,645 · 7
R42$2,968,040 · 1
R21$1,758,721 · 4
R41$1,168,256 · 2
K08$625,050 · 1
R56$433,732 · 1
Top collaborators
- Robert S. Daum5 shared
- Jean Claire Lee5 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPathogenPreventFutureMediatingIn VivoBaseVaccinesIn VitroAntibodiesResistanceVaccinationSerumImmuneBacteriaDrug ResistanceAcinetobacter BaumanniiPhagocytesCytokineClinical TrialsDoseSepsisMortality Vital StatisticsProteins
Grant awards (57)
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections$983,543
R42 · FY2024 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$788,308
R01 · FY2024 · AI · contact PI
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections$989,399
R42 · FY2023 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$788,017
R01 · FY2023 · AI · contact PI
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections$995,098
R42 · FY2022 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$750,854
R01 · FY2022 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$694,204
R01 · FY2021 · AI · contact PI
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections$293,999
R41 · FY2021 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$697,793
R01 · FY2020 · AI · contact PI
The Surface of Hospitals Intensive Environmental Load Disinfection (SHIELD) Study$308,717
R01 · FY2020 · HS · contact PI
Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections$300,000
R41 · FY2020 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$703,322
R01 · FY2019 · AI · contact PI
Transferrin Combination Therapy to Address Antimicrobial Resistance$645,650
R01 · FY2019 · AI · contact PI
The Surface of Hospitals Intensive Environmental Load Disinfection (SHIELD) Study$499,472
R01 · FY2019 · HS · contact PI
Transferrin As a Novel Approach to Combat Mucormycosis$206,250
R21 · FY2019 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$718,766
R01 · FY2018 · AI · contact PI
Transferrin Combination Therapy to Address Antimicrobial Resistance$689,976
R01 · FY2018 · AI · contact PI
The Surface of Hospitals Intensive Environmental Load Disinfection (SHIELD) Study$500,000
R01 · FY2018 · HS · contact PI
Diabetes and Inflammation During Infection$247,500
R21 · FY2018 · AI · contact PI
Transferrin As a Novel Approach to Combat Mucormycosis$247,500
R21 · FY2018 · AI · contact PI
MAb Passive Vaccination against Acinetobacter baumannii$731,173
R01 · FY2017 · AI · contact PI
Transferrin Combination Therapy to Address Antimicrobial Resistance$706,447
R01 · FY2017 · AI · contact PI
The Surface of Hospitals Intensive Environmental Load Disinfection (SHIELD) Study$499,999
R01 · FY2017 · HS · contact PI
Diabetes and Inflammation During Infection$206,250
R21 · FY2017 · AI · contact PI
Transferrin Combination Therapy to Address Antimicrobial Resistance$664,299
R01 · FY2016 · AI · contact PI
A New Approach to Staphylococcus aureus Vaccine Development - Resubmission 01$264,133
R01 · FY2016 · AI
A New Approach to Staphylococcus aureus Vaccine Development - Resubmission 01$249,382
R01 · FY2016 · AI
A New Approach to Staphylococcus aureus Vaccine Development - Resubmission 01$517,000
R01 · FY2015 · AI
A New Approach to Staphylococcus aureus Vaccine Development - Resubmission 01$517,000
R01 · FY2014 · AI
Monoclonal antibody passive vaccination to treat XDR Acinetobacter infections$428,216
R56 · FY2014 · AI · contact PI
Humanized Monoclonal Antibodies to Treat Acinetobacter Infections$285,895
R41 · FY2014 · AI · contact PI
Acinetobacter virulence and host innunopathogenesis$239,450
R21 · FY2014 · AI · contact PI
Antibody Targeting of KPC and NDM1$229,746
R21 · FY2014 · AI · contact PI
Acinetobacter virulence and host innunopathogenesis$18,493
R21 · FY2014 · AI · contact PI
Antibody Targeting of KPC and NDM1$12,287
R21 · FY2014 · AI · contact PI
Monoclonal antibody passive vaccination to treat XDR Acinetobacter infections$5,516
R56 · FY2014 · AI · contact PI
A New Approach to Staphylococcus aureus Vaccine Development - Resubmission 01$517,000
R01 · FY2013 · AI
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections$331,268
R01 · FY2013 · AI · contact PI
Humanized Monoclonal Antibodies to Treat Acinetobacter Infections$288,362
R41 · FY2013 · AI · contact PI
Acinetobacter virulence and host immunopathogenesis$176,337
R21 · FY2013 · AI · contact PI
Antibody Targeting of KPC and NDM1$174,908
R21 · FY2013 · AI · contact PI
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections$349,285
R01 · FY2012 · AI · contact PI
Mechanisms of Als vaccine protection against S. aureus$360,164
R01 · FY2011 · AI · contact PI
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections$346,248
R01 · FY2011 · AI · contact PI
Mechanisms of Als vaccine protection against S. aureus$361,430
R01 · FY2010 · AI · contact PI
Innate Effectors of rAls3p-N Anti-Candida Vaccine$355,382
R01 · FY2010 · AI · contact PI
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections$346,768
R01 · FY2010 · AI · contact PI
Mechanisms of Als vaccine protection against S. aureus$362,730
R01 · FY2009 · AI · contact PI
Innate Effectors of rAls3p-N Anti-Candida Vaccine$355,382
R01 · FY2009 · AI · contact PI
Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections$347,350
R01 · FY2009 · AI · contact PI
Mechanisms of Als vaccine protection against S. aureus$348,720
R01 · FY2008 · AI · contact PI
Adrenergic Antagonism During Murine Candidiasis$129,330
K08 · FY2008 · AI · contact PI
Mechanisms of Als vaccine protection against S. aureus$353,406
R01 · FY2007 · AI · contact PI
Adrenergic Antagonism During Murine Candidiasis$129,330
K08 · FY2007 · AI · contact PI
Adrenergic Antagonism During Murine Candidiasis$129,330
K08 · FY2006 · AI · contact PI
Adrenergic Antagonism During Murine Candidiasis$118,530
K08 · FY2005 · AI
Adrenergic Antagonism During Murine Candidiasis$118,530
K08 · FY2004 · AI